Loading
A phase 1/2 trial of BCMA CAR-T cells in multiple myeloma, run by Chongqing Precision Biotech Co., Ltd, now recruiting.
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease is a phase 1/2 interventional study registered as NCT04271644 by Chongqing Precision Biotech Co., Ltd, with 80 participants planned, started 2019-04-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: BCMA CAR-T cells.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Chongqing Precision Biotech, Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Chongqing Precision Biotech and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/